<style face="normal" font="default" size="100%">694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)<sup>+</sup>/CD141(BDCA-3)<sup>+</sup> myeloid dendritic cells in solid tumors</style>

Drupal-HighWire